⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for stage iiia bladder cancer ajcc v8

Every month we try and update this database with for stage iiia bladder cancer ajcc v8 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical CystectomyNCT03319745
Stage I Bladder...
Stage II Bladde...
Stage III Bladd...
Stage IIIA Blad...
Stage IIIB Blad...
Pembrolizumab
18 Years - M.D. Anderson Cancer Center
Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based TherapyNCT06263153
Bladder Urothel...
Muscle Invasive...
Stage II Bladde...
Stage IIIA Blad...
Biospecimen Col...
Computed Tomogr...
Durvalumab
Futibatinib
Magnetic Resona...
Radical Cystect...
18 Years - Ohio State University Comprehensive Cancer Center
Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder CancerNCT03617913
Bladder Carcino...
Stage II Bladde...
Stage II Renal ...
Stage II Ureter...
Stage II Urethr...
Stage III Bladd...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IIIA Blad...
Stage IIIB Blad...
Urethral Urothe...
Avelumab
Cisplatin
Fluorouracil
Mitomycin
Quality-of-Life...
Radiation Thera...
18 Years - Mayo Clinic
Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 ExpressionNCT04953104
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Urot...
Recurrent Bladd...
Recurrent Renal...
Recurrent Urete...
Recurrent Ureth...
Recurrent Uroth...
Stage III Bladd...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IIIA Blad...
Stage IIIB Blad...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Stage IVA Bladd...
Stage IVB Bladd...
Unresectable Bl...
Unresectable Re...
Unresectable Ur...
Unresectable Ur...
Unresectable Ur...
Diagnostic Labo...
Nivolumab
Relatlimab
18 Years - M.D. Anderson Cancer Center
Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 ExpressionNCT04953104
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Urot...
Recurrent Bladd...
Recurrent Renal...
Recurrent Urete...
Recurrent Ureth...
Recurrent Uroth...
Stage III Bladd...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IIIA Blad...
Stage IIIB Blad...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Stage IVA Bladd...
Stage IVB Bladd...
Unresectable Bl...
Unresectable Re...
Unresectable Ur...
Unresectable Ur...
Unresectable Ur...
Diagnostic Labo...
Nivolumab
Relatlimab
18 Years - M.D. Anderson Cancer Center
Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial CancerNCT00749892
Recurrent Bladd...
Recurrent Renal...
Recurrent Urete...
Recurrent Ureth...
Stage 0a Bladde...
Stage 0a Renal ...
Stage 0a Ureter...
Stage 0a Urethr...
Stage 0is Bladd...
Stage 0is Renal...
Stage 0is Urete...
Stage 0is Ureth...
Stage II Bladde...
Stage II Renal ...
Stage II Ureter...
Stage II Urethr...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IIIA Blad...
Erlotinib Hydro...
19 Years - M.D. Anderson Cancer Center
Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial CancerNCT00749892
Recurrent Bladd...
Recurrent Renal...
Recurrent Urete...
Recurrent Ureth...
Stage 0a Bladde...
Stage 0a Renal ...
Stage 0a Ureter...
Stage 0a Urethr...
Stage 0is Bladd...
Stage 0is Renal...
Stage 0is Urete...
Stage 0is Ureth...
Stage II Bladde...
Stage II Renal ...
Stage II Ureter...
Stage II Urethr...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IIIA Blad...
Erlotinib Hydro...
19 Years - M.D. Anderson Cancer Center
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial CarcinomaNCT04940299
Clinical Stage ...
Clinical Stage ...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Malignant Solid...
Metastatic Blad...
Metastatic Blad...
Metastatic Lung...
Metastatic Mela...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Uret...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Stage III Bladd...
Stage III Lung ...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IIIA Blad...
Stage IIIA Lung...
Stage IIIB Blad...
Stage IIIB Lung...
Stage IIIC Lung...
Stage IV Bladde...
Stage IV Lung C...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Stage IVA Lung ...
Stage IVB Lung ...
Unresectable Me...
Ipilimumab
Nivolumab
Tocilizumab
18 Years - M.D. Anderson Cancer Center
Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship StudyNCT06350734
Stage 0a Bladde...
Stage 0is Bladd...
Stage I Bladder...
Stage II Bladde...
Stage IIIA Blad...
Non-Interventio...
18 Years - Mayo Clinic
Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder CancerNCT03617913
Bladder Carcino...
Stage II Bladde...
Stage II Renal ...
Stage II Ureter...
Stage II Urethr...
Stage III Bladd...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IIIA Blad...
Stage IIIB Blad...
Urethral Urothe...
Avelumab
Cisplatin
Fluorouracil
Mitomycin
Quality-of-Life...
Radiation Thera...
18 Years - Mayo Clinic
Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder CancerNCT04383743
Stage II Bladde...
Stage IIIA Blad...
Muscle Invasive...
Cisplatin
Doxorubicin
Methotrexate
Pegfilgrastim
Pembrolizumab
Radical Cystect...
Vinblastine Sul...
18 Years - University of Washington
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder CancerNCT03775265
Bladder Urothel...
Muscle Invasive...
Stage II Bladde...
Stage IIIA Blad...
Atezolizumab
Biopsy of Bladd...
Cisplatin
Computed Tomogr...
Cystoscopy
Fluorouracil
Gemcitabine
Magnetic Resona...
Mitomycin
Quality-of-Life...
Radiation Thera...
Survey Administ...
Transurethral R...
18 Years - National Cancer Institute (NCI)
A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients Receiving Chemotherapy Before Radical Cystectomy, Get Moving TrialNCT06040762
Muscle Invasive...
Stage II Bladde...
Stage IIIA Blad...
Best Practice
Exercise Interv...
App-Based Inter...
App-Based Inter...
Interview
Wearable Activi...
Physical Perfor...
Questionnaire A...
18 Years - University of Washington
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted AntibodiesNCT04902040
Advanced Bladde...
Advanced Lung N...
Advanced Malign...
Advanced Melano...
Advanced Merkel...
Advanced Renal ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Stage III Bladd...
Stage III Lung ...
Stage III Renal...
Stage IIIA Blad...
Stage IIIA Lung...
Stage IIIB Blad...
Stage IIIB Lung...
Stage IIIC Lung...
Stage IV Bladde...
Stage IV Lung C...
Stage IV Renal ...
Stage IVA Bladd...
Stage IVA Lung ...
Stage IVB Bladd...
Stage IVB Lung ...
Atezolizumab
Avelumab
Durvalumab
Nivolumab
Pembrolizumab
Plinabulin
Radiation Thera...
18 Years - M.D. Anderson Cancer Center
Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 ExpressionNCT04953104
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Urot...
Recurrent Bladd...
Recurrent Renal...
Recurrent Urete...
Recurrent Ureth...
Recurrent Uroth...
Stage III Bladd...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IIIA Blad...
Stage IIIB Blad...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Stage IVA Bladd...
Stage IVB Bladd...
Unresectable Bl...
Unresectable Re...
Unresectable Ur...
Unresectable Ur...
Unresectable Ur...
Diagnostic Labo...
Nivolumab
Relatlimab
18 Years - M.D. Anderson Cancer Center
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted AntibodiesNCT04902040
Advanced Bladde...
Advanced Lung N...
Advanced Malign...
Advanced Melano...
Advanced Merkel...
Advanced Renal ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Stage III Bladd...
Stage III Lung ...
Stage III Renal...
Stage IIIA Blad...
Stage IIIA Lung...
Stage IIIB Blad...
Stage IIIB Lung...
Stage IIIC Lung...
Stage IV Bladde...
Stage IV Lung C...
Stage IV Renal ...
Stage IVA Bladd...
Stage IVA Lung ...
Stage IVB Bladd...
Stage IVB Lung ...
Atezolizumab
Avelumab
Durvalumab
Nivolumab
Pembrolizumab
Plinabulin
Radiation Thera...
18 Years - M.D. Anderson Cancer Center
Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder CancerNCT04383743
Stage II Bladde...
Stage IIIA Blad...
Muscle Invasive...
Cisplatin
Doxorubicin
Methotrexate
Pegfilgrastim
Pembrolizumab
Radical Cystect...
Vinblastine Sul...
18 Years - University of Washington
Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder CancerNCT05581589
Muscle Invasive...
Stage II Bladde...
Stage IIIA Blad...
Lymphadenectomy
Radical Cystect...
Sacituzumab Gov...
18 Years - University of Washington
Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported OutcomesNCT04501913
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Clinical Stage ...
Hepatobiliary N...
Malignant Diges...
Malignant Femal...
Malignant Genit...
Malignant Neopl...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Postneoadjuvant...
Stage 0 Colorec...
Stage 0a Bladde...
Stage 0is Bladd...
Stage I Bladder...
Stage I Cervica...
Stage I Colorec...
Stage I Ovarian...
Stage I Prostat...
Stage I Renal C...
Stage I Uterine...
Stage IA Cervic...
Stage IA Ovaria...
Stage IA Uterin...
Stage IA1 Cervi...
Stage IA2 Cervi...
Stage IB Cervic...
Stage IB Ovaria...
Stage IB Uterin...
Stage IB1 Cervi...
Stage IB2 Cervi...
Stage IC Ovaria...
Stage II Bladde...
Stage II Cervic...
Stage II Colore...
Stage II Ovaria...
Stage II Prosta...
Stage II Renal ...
Stage II Uterin...
Stage IIA Cervi...
Stage IIA Color...
Stage IIA Ovari...
Stage IIA Prost...
Stage IIA1 Cerv...
Stage IIA2 Cerv...
Stage IIB Cervi...
Stage IIB Color...
Stage IIB Ovari...
Stage IIB Prost...
Stage IIC Color...
Stage IIC Prost...
Stage III Bladd...
Stage III Cervi...
Stage III Color...
Stage III Ovari...
Stage III Prost...
Stage III Renal...
Stage III Uteri...
Stage IIIA Blad...
Stage IIIA Cerv...
Stage IIIA Colo...
Stage IIIA Ovar...
Stage IIIA Pros...
Stage IIIA Uter...
Stage IIIA1 Ova...
Stage IIIA2 Ova...
Stage IIIB Blad...
Stage IIIB Cerv...
Stage IIIB Colo...
Stage IIIB Ovar...
Stage IIIB Pros...
Stage IIIB Uter...
Stage IIIC Colo...
Stage IIIC Ovar...
Stage IIIC Pros...
Stage IIIC Uter...
Stage IIIC1 Ute...
Stage IIIC2 Ute...
Stage IV Bladde...
Stage IV Cervic...
Stage IV Colore...
Stage IV Ovaria...
Stage IV Prosta...
Stage IV Renal ...
Stage IV Uterin...
Stage IVA Bladd...
Stage IVA Cervi...
Stage IVA Color...
Stage IVA Ovari...
Stage IVA Prost...
Stage IVA Uteri...
Stage IVB Bladd...
Stage IVB Cervi...
Stage IVB Color...
Stage IVB Ovari...
Stage IVB Prost...
Stage IVB Uteri...
Stage IVC Color...
Patient Monitor...
Questionnaire A...
18 Years - City of Hope Medical Center
Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 ExpressionNCT04953104
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Urot...
Recurrent Bladd...
Recurrent Renal...
Recurrent Urete...
Recurrent Ureth...
Recurrent Uroth...
Stage III Bladd...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IIIA Blad...
Stage IIIB Blad...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Stage IVA Bladd...
Stage IVB Bladd...
Unresectable Bl...
Unresectable Re...
Unresectable Ur...
Unresectable Ur...
Unresectable Ur...
Diagnostic Labo...
Nivolumab
Relatlimab
18 Years - M.D. Anderson Cancer Center
Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder CancerNCT05581589
Muscle Invasive...
Stage II Bladde...
Stage IIIA Blad...
Lymphadenectomy
Radical Cystect...
Sacituzumab Gov...
18 Years - University of Washington
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: